| Title |
Denosumab: an Emerging Therapy in Pediatric Bone Disorders
|
|---|---|
| Published in |
Current Osteoporosis Reports, June 2017
|
| DOI | 10.1007/s11914-017-0380-1 |
| Pubmed ID | |
| Authors |
Alison M. Boyce |
| Abstract |
Denosumab is an inhibitor of receptor activator of nuclear factor kappa-B ligand (RANKL), and has emerged as an important novel therapy for skeletal disorders. This article examines the use of denosumab in children. Considerable safety and efficacy data exists for denosumab treatment of adults with osteoporosis, bone metastases, and giant cell tumors. Pediatric data is limited; however, evidence suggests denosumab may be beneficial in decreasing bone turnover, increasing bone density, and preventing growth of certain skeletal neoplasms in children. Denosumab's effect on bone turnover is rapidly reversible after drug discontinuation, representing a key difference from bisphosphonates. Rebound increased bone turnover has led to severe hypercalcemia in several pediatric patients. Denosumab is a promising therapy for pediatric skeletal disorders. At present, safety concerns related to rebounding bone turnover and mineral homeostasis impact use of denosumab in children. Research is needed to determine if and how these effects can be mitigated. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 111 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 111 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 15 | 14% |
| Researcher | 14 | 13% |
| Student > Postgraduate | 9 | 8% |
| Student > Ph. D. Student | 8 | 7% |
| Student > Bachelor | 7 | 6% |
| Other | 21 | 19% |
| Unknown | 37 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 38% |
| Biochemistry, Genetics and Molecular Biology | 5 | 5% |
| Engineering | 4 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Nursing and Health Professions | 3 | 3% |
| Other | 8 | 7% |
| Unknown | 46 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2022.
All research outputs
#6,486,187
of 25,164,268 outputs
Outputs from Current Osteoporosis Reports
#125
of 603 outputs
Outputs of similar age
#94,617
of 322,602 outputs
Outputs of similar age from Current Osteoporosis Reports
#6
of 18 outputs
Altmetric has tracked 25,164,268 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 603 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,602 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.